stockrow
Friday 6 November 2026
Export SUPN’s income statement to Excel — free account
Indivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
26.43
0.31
−1.16%
Follow SUPN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
21.23 | 15.09 | 14.20 | 9.66 |
P/S ratio |
3.62 | 2.93 | 3.67 | 3.08 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 145.87 | |
P/Operating CF |
(20.29) | (419.95) | 21.32 | 43.61 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.72 | 3.19 | 3.89 | 3.57 | |
EV/EBITDA |
16.34 | 11.74 | 11.85 | 8.58 | |
EV/Operating CF |
(170.70) | (37.11) | (129.41) | 51.04 | |
EV/FCF |
(48.52) | (21.23) | (45.81) | 168.98 | |
Quick Ratio |
0.49 | 0.59 | 0.59 | 0.45 | |
Current Ratio |
0.71 | 0.86 | 0.84 | 0.61 | |
Net Debt/EBITDA |
1.46 | 2.21 | 1.64 | 1.00 | |
Debt/Assets |
26.56% | 40.60% | 39.50% | 36.64% | |
Debt/Equity |
(3.26) | (3.37) | (2.34) | (8.13) | |
Asset Turnover |
0.98 | 1.00 | 0.99 | 1.00 | |
Operating CF/Net income |
(2.15) | (0.10) | 1.88 | 0.71 | |
Capex/Depreciation |
(4.80) | (5.00) | (2.33) | (7.00) | |
Interest Coverage |
13.33 | 19.57 | 79.50 | 90.50 | |
Research and Development Expense of Revenue |
5.88% | 5.05% | 3.50% | 1.40% | |
Selling, General and Administrative Expense of Revenue |
52.94% | 39.12% | 35.57% | 33.43% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
1.40% | 2.84% | 3.21% | 2.25% | |
Graham Net Nets |
(0.14) | (0.18) | (0.15) | (0.14) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
4.71% | 6.63% | 7.04% | 10.35% | |
Free Cash Flow Yield |
(2.12%) | (5.13%) | (2.31%) | 0.69% | |
Revenue per Share |
2.86 | 2.56 | 2.88 | 3.02 | |
Operating CF per Share |
(1.77) | (0.07) | 1.92 | 0.82 | |
Capex per Share |
(0.19) | (0.16) | (0.06) | (0.12) | |
Free Cash Flow per Share |
(1.96) | (0.23) | 1.87 | 0.70 | |
Cash per Share |
1.56 | 1.41 | 1.87 | 2.58 | |
Shareholders Equity per Share |
(0.78) | (1.16) | (1.75) | (0.51) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.78) | (1.16) | (1.75) | (0.51) | |
Free Cash Flow |
(245.00) | (29.00) | 222.00 | 83.00 | |
Working Capital |
(262.00) | (112.00) | (143.00) | (501.00) | |
Capital Expenditures |
(24.00) | (20.00) | (7.00) | (14.00) | |
Net Current Asset Value |
(648.00) | (674.00) | (716.00) | (592.00) | |
EV/EBIT |
17.59 | 12.41 | 12.33 | 8.80 | |
Capex to Sales |
0.07 | 0.06 | 0.02 | 0.04 | |
Price to Operating Income |
17.12 | 11.38 | 11.63 | 7.59 | |
| Other line items | |||||
Average Receivables |
271.00 | 278.50 | 265.00 | 279.00 | |
Average Payables |
233.00 | 180.50 | 201.00 | 198.00 | |
Average Inventory |
160.00 | 157.50 | 149.50 | 152.00 | |
Average Assets |
1,258.50 | 1,286.00 | 1,342.50 | 1,374.00 | |
Average Common Equity |
(218.00) | (215.00) | (232.50) | (133.50) |
Columns are period end dates · fundamentals updated 2 Nov 2026